The Role of Exploratory Drug Metabolism and Pharmacokinetics in New Drug Research: Case Study-Selection of a Thrombin Receptor Antagonist for Development

The Role of Drug Metabolism in Drug Discovery: A Case Study in the Selection of an Oxytocin Receptor Antagonist for Development

Toxicologic Pathology ◽

10.1177/019262339502300204 ◽

1995 ◽

Vol 23 (2) ◽

pp. 124-130 ◽

Cited By ~ 9

Author(s):

Shuet-Ling L. Chiu ◽

A. Thompson ◽

Stella H. Vincent ◽

Raul F. Alvaro ◽

Su-Er W. Huskey ◽

...

Keyword(s):

Drug Discovery ◽

Drug Metabolism ◽

Receptor Antagonist ◽

Oxytocin Receptor ◽

Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

Circulation ◽

10.1161/circulationaha.115.015471 ◽

2015 ◽

Vol 131 (12) ◽

pp. 1041-1043 ◽

Cited By ~ 7

Author(s):

Shinichi Goto ◽

Shinya Goto

Keyword(s):

Myocardial Infarction ◽

Clinical Trial ◽

Secondary Prevention ◽

Receptor Antagonist ◽

Patient Population ◽

Thrombin Receptor ◽

Large Clinical Trial ◽

Ischemic Events ◽

Thrombin Receptor Antagonist ◽

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2015.02.043 ◽

2015 ◽

Vol 115 (10) ◽

pp. 1325-1332 ◽

Cited By ~ 11

Author(s):

Jan H. Cornel ◽

Pierluigi Tricoci ◽

Yuliya Lokhnygina ◽

David J. Moliterno ◽

Lars Wallentin ◽

...

Keyword(s):

Receptor Antagonist ◽

Acute Coronary Syndromes ◽

Thrombin Receptor ◽

St Segment Elevation ◽

St Segment ◽

Coronary Syndromes ◽

Stakeholder Analysis Case Study: Selection of New York City for Amazon “HQ2”

The Palgrave Encyclopedia of Interest Groups, Lobbying and Public Affairs ◽

10.1007/978-3-030-13895-0_8-1 ◽

2020 ◽

pp. 1-13

Author(s):

Jason Voiovich

Keyword(s):

New York ◽

New York City ◽

York City ◽

Stakeholder Analysis ◽

Study Selection ◽

Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

American Heart Journal ◽

10.1016/j.ahj.2016.05.012 ◽

2016 ◽

Vol 178 ◽

pp. 176-184 ◽

Cited By ~ 4

Author(s):

Luciana V. Armaganijan ◽

Karen P. Alexander ◽

Zhen Huang ◽

Pierluigi Tricoci ◽

Claes Held ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Efficacy And Safety ◽

St Segment Elevation ◽

Coronary Syndrome ◽

St Segment ◽

Thrombin Receptor Antagonist ◽

Effect Of Age

The Role of Preclinical Drug Metabolism in New Drug Development From the View Point of Industry

Drug Metabolism and Pharmacokinetics ◽

10.2133/dmpk.13.supplement_148 ◽

1998 ◽

Vol 13 (supplement) ◽

pp. 148-148

Author(s):

Shuet-Hing Lee Chiu

Keyword(s):

Drug Metabolism ◽

Drug Development ◽

View Point ◽

New Drug ◽

New Drug Development

Convergent Synthesis of Both Enantiomers of 4-Hydroxypent-2-ynoic Acid Diphenylamide for a Thrombin Receptor Antagonist Sch 530348 and Himbacine Analogues

Advanced Synthesis & Catalysis ◽

10.1002/adsc.200900322 ◽

2009 ◽

Vol 351 (14-15) ◽

pp. 2351-2357 ◽

Cited By ~ 5

Author(s):

Alex Zaks ◽

Maria Tamarez ◽

Tao Li

Keyword(s):

Receptor Antagonist ◽

Thrombin Receptor ◽

Convergent Synthesis ◽

Sch 530348 ◽

Inhibitory effects of FR171113, a novel, thrombin receptor antagonist, on platelet aggregation and thrombosis model in guinea-pigs

The Japanese Journal of Pharmacology ◽

10.1016/s0021-5198(19)40542-8 ◽

1998 ◽

Vol 76 ◽

pp. 106

Author(s):

Yasuko Kato ◽

Yasuhiro Kita ◽

Mie Nishio ◽

Yoshimi Hirasawa ◽

Kayoko Senzaki ◽

...

Keyword(s):

Platelet Aggregation ◽

Receptor Antagonist ◽

Guinea Pigs ◽

Thrombin Receptor ◽

Inhibitory Effects ◽

Thrombosis Model ◽

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale

American Heart Journal ◽

10.1016/j.ahj.2009.07.001 ◽

2009 ◽

Vol 158 (3) ◽

pp. 327-334.e4 ◽

Cited By ~ 93

Author(s):

The TRA•CER Executive and Steering Committees

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Study Design ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial

European Heart Journal ◽

10.1093/eurheartj/eht104 ◽

2013 ◽

Vol 34 (23) ◽

pp. 1723-1731 ◽

Cited By ~ 25

Author(s):

S. Leonardi ◽

P. Tricoci ◽

H. D. White ◽

P. W. Armstrong ◽

Z. Huang ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽